These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26332597)

  • 21. Benefit assessment in Germany: implications for price discounts.
    Theidel U; von der Schulenburg JM
    Health Econ Rev; 2016 Dec; 6(1):33. PubMed ID: 27485438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Risk-benefit evaluation of medicinal products. An element of Health Technology Assessment].
    Hart D
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):204-14. PubMed ID: 15726462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic trials in oncology. Legal aspects].
    Hart D
    Strahlenther Onkol; 1996 Nov; 172(11):589-95. PubMed ID: 8975390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland.
    Lebioda A; Gasche D; Dippel FW; Theobald K; Plantör S
    Health Econ Rev; 2014 Dec; 4(1):31. PubMed ID: 26208931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.
    ; ;
    Health Qual Life Outcomes; 2006 Oct; 4():79. PubMed ID: 17034633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restrictions on the conduct of advertising of medicinal products in Poland and their violations.
    Czerw A; Marek EM
    Acta Pol Pharm; 2013; 70(4):769-76. PubMed ID: 23923402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A call to restructure the drug development process: government over-regulation and non-innovative late stage (Phase III) clinical trials are major obstacles to advances in health care.
    Jones TC
    Sci Eng Ethics; 2005 Oct; 11(4):575-87. PubMed ID: 16279756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Methodology for analysing quality-of-life data in the benefit assessment of pharmaceuticals].
    Leverkus F
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(2-3):111-9. PubMed ID: 24780708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY.
    Dintsios CM; Schlenkrich S
    Int J Technol Assess Health Care; 2018 Jan; 34(2):196-204. PubMed ID: 29455689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory guideline for biosimilar products in Korea.
    Suh SK; Park Y
    Biologicals; 2011 Sep; 39(5):336-8. PubMed ID: 21784653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.
    Dabisch I; Dethling J; Dintsios CM; Drechsler M; Kalanovic D; Kaskel P; Langer F; Ruof J; Ruppert T; Wirth D
    Health Econ Rev; 2014 Jan; 4(1):2. PubMed ID: 24460706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Consequences of the German AMNOG for the identification of study objectives to demonstrate clinical efficacy and cost effectiveness of innovative drugs].
    Götte D
    Dtsch Med Wochenschr; 2012 Feb; 137(6):274-80. PubMed ID: 22270904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany.
    Dintsios CM; Beinhauer I
    Health Econ Rev; 2020 Mar; 10(1):7. PubMed ID: 32172494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How to improve the clinical development paradigm and its division into phases I, II and III.
    Bamberger M; Moore N; Lechat P;
    Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus.
    Hennekens CH; Hebert PR; Schneider WR; O'Brien P; Demets D; Borer JS
    Contemp Clin Trials; 2010 Sep; 31(5):411-3. PubMed ID: 20601161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.
    Willke RJ; Burke LB; Erickson P
    Control Clin Trials; 2004 Dec; 25(6):535-52. PubMed ID: 15588741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical trials in children--between the expectations of scientific requirements, the assurance of proven treatment and ethical demands].
    Lehmann B; Mentzer D; Fischer T; Mallinckrodt-Pape K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):410-6. PubMed ID: 19266173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.